Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without ...

As part of a $93 million grant package, the Cancer Prevention and Research Institute of Texas, known for funding ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

A variant in the IL-7 gene may predict which patients with kidney cancer are more likely to experience side effects from immunotherapy.

Parker Institute showcases breakthroughs in immunotherapy at ASCO 2025 as CEO Dr. Karen Knudsen receives prestigious honor.

Intermountain Health is now offering a national first-of-its kind expansion of CAR-T Cell Therapy, bringing cutting-edge cancer care closer to patients in ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

Equity Insider News Commentary – With early onset cancer rates on the rise and funding being cut to NIH, the future for cancer patients is increasingly being shaped not by public institutions, but by ...

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a bispecific antibody newly licensed by Pfizer.